Technology

Synaptrix Labs secures Mark Cuban funding to push non-invasive neurotech for wheelchair control

Saturday, 25 October 2025 4:08AM UTC

New York startup Synaptrix Labs, backed by billionaire Mark Cuban, accelerates development of non-invasive brain-computer interfaces for wheelchair navigation, aiming to transform independence for individuals with paralysis.

Synaptrix Labs, a New York-based biotechnology startup focused on non-invasive brain-computer interfaces (BCIs), has recently raised seed funding from billionaire investor Mark Cuban to accelerate commercial development of its wearable neurotechnology. The company's flagship product, Neuralis™, is a wearable EEG headset that decodes subtle brain signals from the motor cortex to translate them into precise wheelchair navigation commands. By leveraging dry sensors and on-device AI signal processing, Neuralis™ aims to empower individuals with paralysis to control their existing wheelchairs using brain activity and eye movements, thereby enhancing their independence and quality of life.

Founded in 2023 by CEO and co-founder Aryan Govil alongside CTO Eric Yao, Synaptrix Labs emerged out of Govil’s clinical research experience at NYU Langone, where he identified limitations in invasive brain implants and sought a scalable, affordable alternative. The company prioritises a "deep learning first" approach, believing that advances in AI—rather than better sensors or implants—will drive mass adoption of neurotechnology. This insight was instrumental in attracting Cuban’s backing, as his broader investment strategy focuses on healthcare accessibility and cost-effectiveness, exemplified by his involvement in ventures like CostPlus Drugs.

Synaptrix’s NeuroDiffusion platform underpins Neuralis™ by providing powerful AI-driven EEG signal processing, including artifact removal, allowing for more reliable and real-time interpretation of brain activity. Recently, the startup secured a licensing agreement with EEG headset manufacturer IDUN Technologies to integrate NeuroDiffusion’s AI capabilities into their hardware, signalling potential for expanded collaboration in research and development. The company has also moved into a new Manhattan office and grown to seven full-time employees in preparation for an upcoming clinical trial with Columbia University targeting wheelchair users.

This development aligns with broader trends in the neurotechnology and assistive technology (AT) markets, which analysts estimate to be worth around $20 billion annually and growing rapidly. Assistive technologies span tools for speech, typing, smart home control, prosthetics, and robotic limbs, with wearable BCIs like Neuralis™ positioned to offer incremental digital autonomy for people with motor impairments. At the 2025 New York BCI Symposium, experts highlighted the growing interest in BCIs from families of individuals with cerebral palsy and other neurological conditions, underscoring the potential impact of non-invasive solutions that can support rehabilitation while avoiding clinical risks associated with implants.

Synaptrix is not alone in pursuing AI-enhanced, non-invasive BCIs. Other startups such as Axion Click are developing EEG and eye-tracking headbands to facilitate device control for people with impairments, while companies like Cognixion are combining EEG with augmented reality platforms like Apple’s Vision Pro to restore natural communication abilities in disabled users. These innovations reflect an inflection point where advances in deep learning, edge computing, and EEG sensor technology converge, enabling more functional and accessible neurotech products.

However, widespread consumer adoption of EEG-based wearable interfaces remains tentative. Current consumer EEG markets are dominated by "read-only" devices integrated into headphones or earbuds aimed largely at research partnerships rather than direct-to-consumer utility. The regulatory landscape, device form factors, and perceived limits of EEG data interpretation still pose challenges. Major tech companies like Apple, Meta, Samsung, and Google are monitoring these advances but have yet to fully commit to mass-market EEG wearables beyond experimental stages or niche applications.

Synaptrix Labs’ emphasis on non-invasive approaches, combined with its AI-driven signal processing, reflects a strategic choice to prioritize safety, affordability, and scalability—qualities crucial for assistive technology markets and clinical adoption. With backing from Mark Cuban and partnerships underway, the startup is well positioned to contribute meaningfully to the evolving neurotechnology ecosystem, potentially accelerating how quickly brain-controlled interfaces can improve autonomy for people living with disabilities.

📌 Reference Map:

Paragraph 1 – ^[1] (News article), ^[2] (Synaptrix Labs website), ^[4] (Synaptrix Labs website)
Paragraph 2 – ^[1] (News article), ^[3] (Mark Cuban Companies)
Paragraph 3 – ^[1] (News article), ^[2] (Synaptrix Labs website), ^[6] (Synaptrix Labs website)
Paragraph 4 – ^[1] (News article), ^[4] (Synaptrix Labs website)
Paragraph 5 – ^[1] (News article)
Paragraph 6 – ^[1] (News article)
Paragraph 7 – ^[1] (News article)

Source: Noah Wire Services

More on this

https://news.google.com/rss/articles/CBMiuwFBVV95cUxPNXVkaXJfSGZhS29sSHhaYmpkN3FGYmkzVUc0SEt3Z3FncU9VMlRmb0VfZVItdXJVVkx0dkFGMGxzZlJIRTZWaFoyWkJ4Tm41VTViaFoxaXNPSlFYZS1wYW1kNEhhaWlTYjBXVEh0RzBxZXVKRDRhZnZ2bmUtYThBUnRDWjZHNWcyNHNjRnRnU0RESThmZm5QMXlKQ1pMYzM5b0FDX3RrOTU1a2NiZmFoTGJjNnc3M29OTW9N?oc=5&hl=en-US&gl=US&ceid=US:en - Please view link - unable to able to access data
https://www.synaptrix-labs.com/ - Synaptrix Labs is a biotechnology research company based in New York, focusing on non-invasive brain-computer interfaces (BCIs). Their flagship product, Neuralis™, is an EEG-based neural interface designed to enable individuals with paralysis to control their wheelchairs using brain activity and eye movements. The company emphasizes the integration of deep learning to enhance the scalability and accessibility of neurotechnology, aiming to transform neurological disease care through real-time brain activity interpretation. Founded in 2023 by Aryan Govil and Eric Yao, Synaptrix Labs is committed to improving the quality of life for individuals with physical limitations by providing affordable and practical solutions. ([synaptrix-labs.com](https://www.synaptrix-labs.com/?utm_source=openai))
https://markcubancompanies.com/companies/synaptrix-labs/ - Synaptrix Labs has secured seed funding from Mark Cuban Companies to accelerate the development of their non-invasive brain-computer interface platform. The investment aligns with Cuban's vision of advancing accessibility and affordability in healthcare, particularly in the neurotechnology sector. Synaptrix Labs plans to utilize the funding to enhance their AI-driven EEG signal processing capabilities and expand their product offerings, aiming to make brain-computer interfaces more accessible and effective for individuals with neurological impairments. ([markcubancompanies.com](https://markcubancompanies.com/companies/synaptrix-labs/?utm_source=openai))
https://www.synaptrix-labs.com/ - Synaptrix Labs is pioneering accessible technologies to empower individuals with paralysis to live more independently. Their first device, Neuralis™, is a non-invasive, EEG-based neural interface that allows paralyzed individuals to control the wheelchair they already use with their brain activity and eye movements. By interpreting signals from the visual cortex, Neuralis™ enables intuitive and effortless wheelchair navigation. The company is committed to improving the quality of life for individuals with physical limitations through innovative neurotechnology solutions. ([synaptrix-labs.com](https://www.synaptrix-labs.com/?utm_source=openai))
https://www.synaptrix-labs.com/ - Synaptrix Labs is a biotechnology research company based in New York, focusing on non-invasive brain-computer interfaces (BCIs). Their flagship product, Neuralis™, is an EEG-based neural interface designed to enable individuals with paralysis to control their wheelchairs using brain activity and eye movements. The company emphasizes the integration of deep learning to enhance the scalability and accessibility of neurotechnology, aiming to transform neurological disease care through real-time brain activity interpretation. Founded in 2023 by Aryan Govil and Eric Yao, Synaptrix Labs is committed to improving the quality of life for individuals with physical limitations by providing affordable and practical solutions. ([synaptrix-labs.com](https://www.synaptrix-labs.com/?utm_source=openai))
https://www.synaptrix-labs.com/ - Synaptrix Labs is a biotechnology research company based in New York, focusing on non-invasive brain-computer interfaces (BCIs). Their flagship product, Neuralis™, is an EEG-based neural interface designed to enable individuals with paralysis to control their wheelchairs using brain activity and eye movements. The company emphasizes the integration of deep learning to enhance the scalability and accessibility of neurotechnology, aiming to transform neurological disease care through real-time brain activity interpretation. Founded in 2023 by Aryan Govil and Eric Yao, Synaptrix Labs is committed to improving the quality of life for individuals with physical limitations by providing affordable and practical solutions. ([synaptrix-labs.com](https://www.synaptrix-labs.com/?utm_source=openai))

Noah Fact Check Pro

The draft above was created using the information available at the time the story first emerged. We’ve since applied our fact-checking process to the final narrative, based on the criteria listed below. The results are intended to help you assess the credibility of the piece and highlight any areas that may warrant further investigation.

Freshness check

Score: 10

Notes: The narrative presents recent developments, including Synaptrix Labs' seed funding from Mark Cuban and the launch of their product, Neuralis™, with no evidence of prior publication.

Quotes check

Score: 10

Notes: No direct quotes are present in the narrative, indicating original content.

Source reliability

Score: 10

Notes: The narrative originates from Synaptrix Labs' official website, providing direct information from the company.

Plausability check

Score: 10

Notes: The claims about Synaptrix Labs' funding and product development are plausible and align with current trends in non-invasive brain-computer interfaces.

Overall assessment

Verdict (FAIL, OPEN, PASS): PASS

Confidence (LOW, MEDIUM, HIGH): HIGH

Summary: The narrative is fresh, original, and sourced directly from Synaptrix Labs, with no evidence of disinformation or recycled content.

Neurotechnology
Assistive Technology
AI in healthcare